Untitled

CAS NO: 4415-87-6 NAME:Cyclobutane-1,2,3,4-tetracarboxylic dianhydride

Details：

For more information, please contact our customer service center.

protein binding

Wuhan Heyan biology has accumulated more than 10 years of experience in recombinant protein expression and purification services. Wuhan Heyan biology has a variety of protein expression systems, including prokaryotic protein expression system, yeast protein expression system, insect cell protein expression system (baculovirus) and mammalian cell protein expression system, and has a variety of fusion technologies, It can provide you with a variety of options in protein expression and purification. From scheme design, gene optimization, expression condition optimization to purification technology system, so as to improve the expression level of your target protein.

Multiple protein expression systems:

Wuhan Heyan biology provides a variety of recombinant protein systems for you to choose, which can be flexibly selected from the aspects of price, cycle, advantages and disadvantages to meet your different scientific research needs.

Picture upload

Our advantages

Professional team

The backbone of scientific research is composed of experienced Chinese doctors, German doctors and enterprise managers who have worked in the pharmaceutical field in the United States for many years. The company has more than 800 employees, and about 50% have doctoral or master's degrees; More than 10% of employees have foreign educational background and work experience.

Perfect service system platform

Wuhan Heyan biology has a 30000 square meter R & D laboratory and high-end instruments and equipment. The structural biology laboratory is equipped with a molecular cloning room and a drug discovery and screening platform based on protein crystallography to support structure based drug development, from the confirmation of new targets to the final structure confirmation.

Authoritative certification

protein binding

https://heyanbiotech.cn/

Reporter gene

Reporter gene analysis is very important for studying the regulation of cis or trans acting factors on gene expression or measuring the activation of cellular signal pathways. In these analyses, reporter genes act as substitutes for the study of gene coding regions. The reporter gene structure includes one or more gene regulatory elements being analyzed, the structural sequence of the reporter gene and the sequence required to form functional mRNA. After introducing the reporter construct into cells and experimental treatment, the expression level of the reporter gene is monitored by quantifying the reporter protease activity, which is used to characterize regulatory sequences, transcription factor activity, cellular signals or signal pathways.

The two functional parts of the gene include coding region and promoter region. The coding region is a DNA sequence containing protein information generated by transcription and translation mechanisms. Promoter region is a specific DNA sequence that regulates gene transcription and can activate or inhibit gene expression.

Reporter gene analysis is usually used to measure the regulatory ability of unknown DNA sequences. This is achieved by connecting an unknown promoter sequence to an easy to detect reporter gene, and the products of the reporter gene can be easily detected and quantitatively measured.

Common reporter genes include β- Galactosidase, luciferase β- Lactamase, alkaline phosphatase and green fluorescent protein (GFP). Luminescence, absorbance and fluorescence detection methods are usually used to measure the expression of reporter gene proteins. Back to Home pageBack to Functional Assay pageBack to Selectivity/Safety Evaluation pageBack to Customization Service pageBack to Popular Drug Targets pageFor more information, please contact us

Reporter gene

https://cn.heyanbiotech.cn/a/FunctionalAssayServices/Reporter-gene.html

tumor markers

The best strategy to deal with tumor is early diagnosis, which can increase the cure rate to 83%. The most effective method for early diagnosis of tumor is to find tumor markers in body fluid, especially protein markers. Malignant tumor is a major disease threatening human life and health. Although the treatment of tumor has made great progress through the efforts of scientists and clinicians, the high mortality has not been effectively controlled. According to the latest cancer incidence rate data from the National Cancer Center (the cancer registry of 31 provinces and autonomous regions in 2017) collected from the National Cancer Registry in 2017, the number of new cases of malignant tumors in the country is 3 million 804 thousand. The standardized incidence rate is 174.0/10 million, which is slightly lower than the world average of 182.3/10 million. However, the incidence of cancer in China accounts for about 22% of the world, and the number of patients is the first in the world. There are more than 2 million cancer deaths in China, accounting for about 27% of the world. The standardized mortality rate is 122.2/100000, higher than the world average of 102.4/100000. Due to the lack of early screening for cancer and late treatment time, the 5. Year survival rate of cancer in China is only 30.9%, compared with more than 70% in developed countries. The complex pathogenesis of tumor, few effective screening technologies and low level of early diagnosis technology lead to the late detection of tumor, which makes the situation of tumor prevention in China severe. Tumor markers are a kind of substances that change abnormally due to the expression of related genes or collective response to tumor in the process of tumor cell occurrence, proliferation, metastasis or recurrence. Tumor markers have been discovered for more than 100 years. Since the 1960s, they have been widely used in clinic and played an important role in tumor discovery and treatment. With the development of biotechnology, various new markers have been found gradually, and the specificity and sensitivity have been improved. According to clinical evaluation criteria, tumor markers should have the following characteristics: (1) It must be produced by malignant tumor cells and can be detected in blood, tissue fluid, secretory fluid or tumor tissue; (2) In normal tissues or benign tumors, the content is low; (3) Tumor markers of a tumor can be detected in most patients with the tumor; (4) It can be detected before there is no definite tumor diagnosis in clinic; (5) The amount of tumor markers can reflect the size of the tumor; (6) To some extent, it can help to estimate the therapeutic effect and predict the recurrence and metastasis of tumor.

https://cn.heyanbiotech.cn/a/articles/2021/0828/tumor-markers.html